Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA
SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regulatory Authority ofBrazil, ANVISA. Daewoong Pharmaceutical, represented by CEO Seng-ho Jeon and ...
Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill
SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm
Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome
Hair Fill. HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive
technology for scalp rejuvenation and hair growth.
Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines
'Fexuprazan,' Novel drug for Gastroesophageal Reflux Disease, starts its release inthe Philippines... The first case of overseas launch SEOUL, South Korea, Aug. 16, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Jeon Seng-ho, Lee Chang-jae) announced that 'Fuxuprazan' is officially launched i...
Maypharm Launches SEDY FILL, a hyaluronic acid body filler
SEOUL, South Korea and NEW YORK, Aug. 9, 2023 /PRNewswire/ -- Maypharm has launchedSEDY FILL, a hyaluronic acid body filler maximized in effect to guarantee customer satisfaction.SEDY FILL is an injectable dermal filler designed for non-surgical correction of body shape. The uniqueness of its pr...
Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs
– Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical trial inChina aiming to reach 100 countries by 2027" SEOUL, South Korea, July 31, 2023 /PRNewswire/ -- Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for t...
Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet
SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo Tab., the 1st SGLT-2 inhibitor by Korea, expanding its product portfolio. Daewoong Pharmaceutical (Jeon Sen...
Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine
* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOLee Chang-jae and Jeon Sengho) announced on the 25th...
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023
- New investigational data evaluating Fexuprazan in a Korean clinical trial program for healing erosive esophagitis (EE) regardless of food intake, and in a Chinese pivotal clinical trial program for the treatment of EE SEOUL, South Korea and CHICAGO, May 19, 2023 /PRNewswire/ -- Daewoong Pharm...
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio
- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development expertis...
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal
SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- The research results of Daewoong Pharmaceutical's SGLT-2 inhibitor new drug, 'Envlo', have been internationally acknowledged. On April 4, Daewoong Pharmaceutical (CEO Seng-ho Jeon and Chang-jae Lee) announced that the efficacy and safety evalu...
Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration
- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening SEOUL, South Korea and NOTTINGHAM, England, April 18, 2023 /PRNewswire/ -- Daewoong Pharmaceuti...
Maypharm's Hyalmass filler with Hybrid Technology obtained CE to hit Europe and America's market
SEOUL, South Korea and NEW YORK, April 18, 2023 /PRNewswire/ -- Being already popular onSouth Asia market, particularly in Vietnam, Philippines, Thailand, China, for Hybrid Technology and highly dense HA for long-lasting effect, Hyalmass filler obtains CE to properly enterEurope, America etc mark...
Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries
* Submitted an NDA to Indonesia, Philippines and Thailand * Signed the export contract in Brazil and Mexico in last February * Aiming to enter 50 countries by 2030 SEOUL, South Korea, March 22, 2023 /PRNewswire/ -- Daewoong Pharmaceutical began the advance into the global market in full swin...
Maypharm CO, LTD., launched a new CE filler: Multi-layered Phasic Hyaluronic Acid with lidocaine and CE approved MayFill Filler
SEOUL, South Korea and NEW YORK, Feb. 20, 2023 /PRNewswire/ -- Maypharm, a brand holder of such popular products as Metoo fill, Sedy fill, Metox, Mennus, Hairna, Eyebella, has been busy with developing new products in Aestheticians market. Metoo Fill is the first CE approved filler made by Maypha...
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue
- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 billion according to the accounting of 2022 - Not only stable positioning of Fexuclue but also achievement obtaining a permit of new medicine for Envlo SEOUL, South Korea, Feb. 19, 2023 /PRNewswire/ ...
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks - Development of treatment for pulmonary fibrosis which is unsatisfactory and in high demand, and anticipation for extended adaptability against various rare fibrosis diseases SEOUL, South Korea, Fe...
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region
* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a double-digit royalties on Net Sales * CS Pharmaceuticals will receive exclusive rights for development and commercialization of Bersiporocin for the treatment of IPF and other respiratory indica...
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea
"Expected to change GERD drug market landscape" * Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted toColombia ,Vietnam, and Saudi Arabia * NDA submissions in 11 countries completed in the shortest time among K...
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030
* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36th new drug from the Ministry of Food and Drug Safety * Plans to enter the type 2 diabetes global market worth $71.4 billion * Provides new and broad treatment options for patients with insufficie...
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue
* Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue topsKRW 40.4 billion * Fexuclue, a new drug released last July, shows steep growth in market share in Korea * Nabota enters the European market and Fexuclue enters wide use as in prescriptions for gastrit...
